Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BAFFR-CAR T cells |
Synonyms | |
Therapy Description |
BAFFR-CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets B-cell activating factor receptor (BAFF-R) and containing TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially result in cytotoxic effects against tumor cells (PMID: 31554741). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAFFR-CAR T cells | Autologous BAFFR-CAR-expressing T-cells | BAFFR-CAR T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets B-cell activating factor receptor (BAFF-R) and containing TNFRSF9 (4-1BB) and CD3zeta signaling domains, which potentially result in cytotoxic effects against tumor cells (PMID: 31554741). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05370430 | Phase I | BAFFR-CAR T cells | BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | Recruiting | USA | 0 |
NCT04690595 | Phase I | BAFFR-CAR T cells | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | Recruiting | USA | 0 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |